Nicholas A. Boyle, Ph.D., is vice president, corporate strategy and business development at Tocagen. Previously, Dr. Boyle was director of corporate development at Spectrum Pharmaceuticals Inc. Among other responsibilities at Spectrum, Dr. Boyle completed numerous strategic licensing agreements, including transactions valued up to approximately $700 million for a Phase 3 cancer compound with Allergan, Nippon Kayaku and Handok.
During his scientific career, Dr. Boyle was team leader for antiviral and anticancer drug discovery programs at Biota Inc. and synthesized anti-stroke drug candidates at SmithKline Beecham (now GSK). Dr. Boyle is an author or inventor on 15 scientific articles/patents.
Nicholas holds a master’s degree in business administration from the University of California, San Diego, a doctorate in organic chemistry from Sheffield University and a bachelor’s degree in medicinal chemistry. He completed his post-doctoral research at The Scripps Research Institute, was a visiting scholar at The University of North Texas and received a Monbusho Fellowship to conduct research at NIAIR, Tsukuba, Japan.